Elicio Therapeutics Inc. (NASDAQ: ELTX)
$5.2400
+0.2100 ( +3.97% ) 10.8K
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.
Market Data
Open
$5.2400
Previous close
$5.0300
Volume
10.8K
Market cap
$54.10M
Day range
$5.0400 - $5.2550
52 week range
$2.9600 - $11.4500
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
ars | Annual reports | 1 | Sep 27, 2024 |
def | Proxies and info statements | 4 | Sep 27, 2024 |
pre | Proxies and info statements | 4 | Sep 17, 2024 |
8-k | 8K-related | 13 | Aug 30, 2024 |
4 | Insider transactions | 1 | Aug 14, 2024 |
10-q | Quarterly Reports | 84 | Aug 13, 2024 |
8-k | 8K-related | 20 | Aug 13, 2024 |
8-k | 8K-related | 19 | Aug 12, 2024 |
4 | Insider transactions | 1 | Jul 02, 2024 |
4 | Insider transactions | 1 | Jul 02, 2024 |